Kapoor, Manav https://orcid.org/0000-0001-6682-940X
Chao, Michael J.
Johnson, Emma C. https://orcid.org/0000-0003-0394-777X
Novikova, Gloriia https://orcid.org/0000-0002-3916-2627
Lai, Dongbing https://orcid.org/0000-0001-7803-580X
Meyers, Jacquelyn L. https://orcid.org/0000-0003-3863-8555
Schulman, Jessica
Nurnberger, John I. Jr https://orcid.org/0000-0002-7674-1767
Porjesz, Bernice
Liu, Yunlong https://orcid.org/0000-0002-2699-626X
,
Hesselbrock, Victor
Kuperman, Samual
Kramer, John
Kamarajan, Chella
Pandey, Ashwini
Bierut, Laura
Rice, John P.
Bucholz, Kathleen K.
Schuckit, Marc
Tischfield, Jay
Brooks, Andrew
Hart, Ronald P.
Almasy, Laura
Dick, Danielle
Salvatore, Jessica
Slesinger, Paul
Foroud, Tatiana https://orcid.org/0000-0002-5549-2212
Edenberg, Howard J. https://orcid.org/0000-0003-0344-9690
Marcora, Edoardo https://orcid.org/0000-0002-3829-4927
Agrawal, Arpana https://orcid.org/0000-0002-0313-793X
Goate, Alison https://orcid.org/0000-0002-0576-2472
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R21AA026388, U10AA008401)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
Article History
Received: 3 November 2020
Accepted: 3 August 2021
First Online: 20 August 2021
Competing interests
: Alison Goate is on the scientific advisory board for Genentech and has served as a consultant for AbbVie and Cognition Therapeutics. Alison Goate is also listed as an inventor on Issued U.S. Patent 8,080,371, “Markers for Addiction” covering the use of certain variants in determining the diagnosis, prognosis, and treatment of addiction. From February, 2021, Manav Kapoor is employee of Regeneron Pharmaceuticals. All other authors declare no competing interest.